REG - ReNeuron Group plc - Block Listing Review and Total Voting Rights
RNS Number : 5776QReNeuron Group plc01 March 2021ReNeuron Group plc
("ReNeuron" or the "Company")
Block Listing Review and Total Voting Rights
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements.
Name:
ReNeuron Group plc
Name of Scheme:
ReNeuron Share Option Schemes
Period of Return:
From 1 September 2020 to 28 February 2021
Balance of unallotted securities under scheme(s) from previous return:
674,687 Ordinary Shares (of 1p each)
Plus: The amount by which the block scheme(s) has been increased since the date of the last Review (if any increase has been applied for):
N/A
Less: Number of securities issued/allotted under scheme(s) during period
11,000
Equals: Balance under scheme(s) not yet issued/allotted at end of period:
663,687 Ordinary Shares
Number and class of securities originally admitted and the date of admission:
20,000 ordinary shares on 13 May 2010
Total Voting Rights
At 28 February 2021, the Company had 56,855,705 Ordinary Shares in issue, each carrying one voting right.
As the Company holds no ordinary shares in treasury, the figure of 56,855,705 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Contacts:
ReNeuron
Olav Hellebø, Chief Executive Officer
Via Walbrook PR
Michael Hunt, Chief Financial Officer
Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)
Ben Maddison, Stewart Wallace
+44 (0)20 7710 7600
Allenby Capital Limited (Joint Broker)
+44 (0)20 3328 5656
James Reeve/George Payne (Corporate Finance)
Tim Sohal (Sales & Corporate Broking)
Walbrook PR (Media & Investor Relations)
+44 (0)20 7933 8780 or reneuron@walbrookpr.com
Paul McManus, Alice Woodings
+44 (0)7980 541 893 / +44 (0)7407 804 654
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. he Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDMSCDKABQABKDNBB
Recent news on ReNeuron
See all newsREG - ReNeuron Group plc - Directorate Change
AnnouncementREG - FTSE Russell - ReNeuron Group
AnnouncementREG - ReNeuron Group plc - Appointment of Administrators
AnnouncementREG - ReNeuron Group plc - Intention to Appoint Administrators
AnnouncementREG - ReNeuron Group plc - Block Listing Review & Total Voting Rights
Announcement